The Patent Finder

NuCana plc

Also on record
Records under this name other than the patents NuCana plc holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 26 patents it holds.

Back to NuCana plc

PatentTitleStatus Expires Confidence
US 10,662,213Gemcitabine prodrugs
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,570,1682' And/Or 5' Amino-Acid Ester Phosphoramidate 3'-Deoxy Adenosine Derivatives as Anti-Cancer Compounds
Formerly held
In force
 · High confidence
In forceHigh confidence
US RE47,589Phosphoramidate compounds and methods of use
Term ended
Term ended Jul 25, 2026 · From the USPTO record
Term endedTerm ended Jul 25, 2026From the USPTO record
US 11,377,467Crystalline Form of Gemcitabine
Lapsed on the fee record
Ended Jul 5, 2026 · High confidence
Lapsed on the fee recordEnded Jul 5, 2026High confidence
US 9,834,577Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
Lapsed on the fee record
Ended Dec 5, 2025 · From the USPTO record
Lapsed on the fee recordEnded Dec 5, 2025From the USPTO record
US 11,040,051Formulation comprising a gemcitabine-prodrug
Lapsed on the fee record
Ended Jun 22, 2025 · From the USPTO record
Lapsed on the fee recordEnded Jun 22, 2025From the USPTO record
US 10,906,929Phosphoramidate nucleoside derivatives as anticancer agents
Lapsed on the fee record
Ended Feb 2, 2025 · From the USPTO record
Lapsed on the fee recordEnded Feb 2, 2025From the USPTO record
US 10,774,104Diastereoselective Synthesis of Phosphate Derivatives
Lapsed on the fee record
Ended Sep 15, 2024 · High confidence
Lapsed on the fee recordEnded Sep 15, 2024High confidence
US 8,263,575Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
Lapsed on the fee record
Ended Sep 11, 2024 · From the USPTO record
Lapsed on the fee recordEnded Sep 11, 2024From the USPTO record
US 9,321,798Phosphoramidite derivatives of gemcitabine for use in the treatment of cancer
Lapsed on the fee record
Ended Apr 26, 2024 · From the USPTO record
Lapsed on the fee recordEnded Apr 26, 2024From the USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited